Transfusion of Ipscs-Derived Leukocytes to Kill Cancer


Here we propose that the rejuvenation of leukocytes with iPSC technology in vitro and transfusion of cancer cellresistant white blood cells back to human body provide a prospective therapy for cancer patients.

Share and Cite:

J. Li, Y. Cui, G. Gao and T. Yuan, "Transfusion of Ipscs-Derived Leukocytes to Kill Cancer," Journal of Cancer Therapy, Vol. 1 No. 1, 2010, pp. 29-30. doi: 10.4236/jct.2010.11004.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. E. Moore, C. P. Rhoads, and C. M. Southam, “Homotransplantation of human cell lines,” Science, Vol. 125, No. 3239, pp. 158–160, 1957.
[2] J. M. Pawelek and A. K. Chakraborty, “The cancer cell-leukocyte fusion theory of metastasis,” Advances in Cancer Research, Vol. 101, pp. 397–444. 2008.
[3] A. M. Hicks, G. Riedlinger, M. C. Willingham, M. A. Alexander-Miller, C. Von Kap-Herr, M. J. Pettenati, A. M. Sanders, H. M. Weir, W. Du, J. Kim, et al., “Transferable anticancer innate immunity in spontaneous regression/complete resistance mice,” Proceedings of the National Academy of Science, USA, Vol. 103, No. 20, pp. 7753–7758, 2006.
[4] J. Yu, M. A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. A. Jonsdottir, V. Ruotti, R. Stewart, et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science, Vol. 318, No. 5858, pp. 1917–1920, 2007.
[5] K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka, “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, Vol. 131, No. 5, pp. 861–872, 2007.
[6] G. Amabile and A. Meissner, “Induced pluripotent stem cells: Current progress and potential for regenerative medicine,” Trends in Molecular Medicine, Vol. 15, No. 2, pp. 59–68, 2009.
[7] D. Kim, C. H. Kim, J. I. Moon, Y. G. Chung, M. Y. Chang, B. S. Han, S. Ko, E. Yang, K. Y. Cha, R. Lanza, et al., “Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins,” Cell Stem Cell, Vol. 4, No. 6, pp. 472–476, 2009.
[8] H. Zhou, S. Wu, J. Y. Joo, S. Zhu, D. W. Han, T. Lin, S. Trauger, G. Bien, S. Yao, Y. Zhu, et al., “Generation of induced pluripotent stem cells using recombinant proteins,” Cell Stem Cell, Vol. 4, No. 5, pp. 381–384, 2009.
[9] T. Lin, R. Ambasudhan, X. Yuan, W. Li, S. Hilcove, R. Abujarour, X. Lin, H. S. Hahm, E. Hao, A. Hayek, et al., “A chemical platform for improved induction of human iPSCs,” Nature Methods, Vol. 6, No. 11, pp. 805–808, 2009.
[10] Y. Shi, Y. ZHao, and H. Deng, “Powering reprogramming with vitamin C,” Cell Stem Cell, Vol. 6, pp.1–2, 2010.
[11] M. A. Esteban, T. Wang, B. Qin, J. Yang, D. Qin, J. Cai, W. Li, Z. Weng, J. Chen, S. Ni, et al., “Vitamin C Enhances the Generation of Mouse and Human Induced Pluripotent Stem Cells,” Cell Stem Cell, 2009.
[12] J. M. Pawelek and A. K. Chakraborty, “Fusion of tumour cells with bone marrow-derived cells: A unifying explanation for metastasis,” Nature Reviews Cancer, Vol. 8, No. 5, pp. 377–386, 2008.
[13] Z. G. Fridlender, J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, and S. M. Albelda, “Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus "N2" TAN,” Cancer Cell, Vol. 16, No. 3, pp. 183–194, 2009.
[14] M. Hannig, H. R. Figulla, H. Sauer, and M. Wartenberg, “Control of leukocyte differentiation from embryonic stem cells upon vasculogenesis and confrontation with tumour tissue,” Journal of Cellular and Molecular Medicine, 2008.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.